Trastuzumab pamirtecan
Antibody–drug conjugate
Also known as DB-1303
Evidence outlook · regulatory review
HER2-Positive Breast Cancer: application under NMPA review
NMPA accepts BLA for trastuzumab pamirtecan (DB-1303) (2026-04-09). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
NCT06265428: Patients were randomly assigned to DB-1303/BNT323 or the active comparator T-DM1 in a Phase 3 trial of about 228 patients, with disease progression (PFS) as the primary measure -- a hard clinical endpoint. However, the study is open-label with no blinding of patients or investigators, and while outside reporting indicates the drug beat T-DM1 on PFS at an interim look, no specific numbers (hazard ratio, medians, or p-value) are available to verify the strength of that result, so this is graded as solid but not top-tier evidence.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 3Endometrial Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06265428 NCT06265428 · HER2-positive Breast Cancer Patients were randomly assigned to DB-1303/BNT323 or the active comparator T-DM1 in a Phase 3 trial of about 228 patients, with disease progression (PFS) as the primary measure -- a hard clinical endpoint. However, the study is open-label with no blinding of patients or investigators, and while outside reporting indicates the drug beat T-DM1 on PFS at an interim look, no specific numbers (hazard ratio, medians, or p-value) are available to verify the strength of that result, so this is graded as solid but not top-tier evidence. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT06265428 | 3 | Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Up to approximately 24 months.) 2027-12 | NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other HER2 drugs
margetuximab, Trastuzumab Deruxtecan, Tucatinib, Zanidatamab, Disitamab Vedotin and 11 more. Compare all 17 HER2 drugs
This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.
This drug's own stage for Endometrial Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Trastuzumab Pamirtecan: this drug | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Dostarlimab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023). | |
| Fruquintinib (Fruzaqla / Elunate) | Phase 3 | Small molecule | VEGFR1/2/3 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08634404 | Phase 3 | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| Puxitatug Samrotecan | Phase 3 | Antibody–drug conjugate | B7-H4 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Rinatabart Sesutecan (Rina-S) | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Govitecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Selinexor | Phase 3 | Small molecule | XPO1 (exportin-1) | not yet graded | No reviewed efficacy summary in this indication | |
| Sotiburafusp Alfa | Phase 3 | Multispecific antibody | PD-L1 / VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| Envafolimab | Phase 2 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4508 | Phase 2(overall) | Small molecule | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Serabelisib | Phase 2 | Small molecule | PI3K alpha (inhibitor) | Weak signal | No reviewed efficacy summary in this indication | |
| 177Lu-DWJ155 | Phase 1(overall) | Radiopharmaceutical | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BL-M17D1 | Phase 1(overall) | Antibody–drug conjugate | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| IMGN-151 | Phase 1 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| KJ015 | Phase 1(overall) | Multispecific antibody | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| MT-304 | Phase 1(overall) | RNA / oligonucleotide | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| NVL-330 | Phase 1(overall) | Small molecule | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| RAD202 | Phase 1(overall) | Radiopharmaceutical | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| GSK6855547 | —(overall) | Small molecule | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Trastuzumab pamirtecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent